Zhejiang CFMoto Power Co Ltd

CFMOTO announced after market close on September 7 that its wholly owned US subsidiary CFP has recently received successive US tariff refunds. From August 14 to September 7, it received a cumulative 54.0324 million US dollars, equivalent to 366 million yuan at the central parity rate of 6.7795. After accounting for income tax, this is expected to affect net profit for 2026 by approximately 256 million yuan, representing 15.31% of the most recent audited net profit attributable to the parent company. To date, the company has received cumulative US tariff and interest refunds totaling 92.6403 million US dollars, equivalent to 628 million yuan, and is expected to affect net profit for 2026 by approximately 440 million yuan, representing 26.26% of net profit attributable to the parent company. The company stated that the profit impact of the refunds will mainly occur in the second half of 2026, with the final audited results prevailing. Previously, the company reported first-half revenue of 13.386 billion yuan, up 35.82% year on year, and net profit attributable to the parent company of 1.065 billion yuan, up 6.26% year on year, with growth across all three major businesses: all-terrain vehicles, fuel motorcycles, and electric two-wheelers.

Recently, multiple A-share listed companies have announced receipt of US tariff refunds. Hanshow Technology's wholly-owned subsidiary in the United States has cumulatively received US tariff and interest refunds totaling 23.1064 million US dollars, equivalent to approximately 157 million yuan. After withholding, the impact on the company's 2026 net profit is approximately 71.1716 million yuan, accounting for 15.75% of the most recent audited net profit. Leyard's consolidated subsidiaries have cumulatively received US tariff and interest refunds totaling 16.5598 million US dollars, equivalent to approximately 112 million yuan. The specific impact on 2026 performance remains to be confirmed. Sirio Pharma's overseas subsidiaries have cumulatively received tariff and interest refunds totaling 11.7029 million US dollars, equivalent to approximately 79.4436 million yuan. Rongjie Health's controlled subsidiaries have cumulatively received 7.252 million US dollars, with an expected impact on the company's net profit attributable to the parent of 17.9599 million yuan, accounting for 24% of the most recent audited net profit. Shanghai Jahwa's wholly-owned overseas subsidiary has cumulatively received tariff and interest refunds of 4.6636 million US dollars, equivalent to approximately 32.322 million yuan, accounting for 12.08% of the company's most recent audited net profit. CFMOTO's wholly-owned subsidiary has cumulatively received US tariff and interest refunds of 38.6079 million US dollars, equivalent to 262 million yuan, with an expected impact on 2026 net profit of approximately 183 million yuan, accounting for 10.95% of the most recent audited net profit. Healthcare Co., Ltd.'s consolidated subsidiaries have cumulatively received US tariff refunds of 2.1324 million US dollars, equivalent to approximately 14.4764 million yuan, to be included in 2026 current profit or loss.

CFMOTO released its 2026 interim report, with net profit attributable to the parent company of 1.065 billion yuan, up 6.26% from the same period last year. Total operating revenue was 13.386 billion yuan, an increase of 3.531 billion yuan from the same period last year, up 35.82% year-on-year, marking five consecutive years of growth. Net cash inflow from operating activities was 2.247 billion yuan, down 6.39% from the same period last year. The company's latest asset-liability ratio was 65.45%, gross margin was 27.26%, and diluted earnings per share was 6.96 yuan.

On the evening of August 12, several listed companies on the Shanghai and Shenzhen stock exchanges released important positive announcements. Suzhou ShuoBeiDe plans to raise no more than 1.096 billion yuan through a private placement, for projects including server cooling modules, lightweight radio-frequency components for smart glasses, and low-earth-orbit satellite communication antennas and modules. Hybio Pharmaceutical signed a cooperation agreement with Shenyang Sunshine Pharmaceutical for a semaglutide injection blood glucose control indication, under which the two parties will carry out development, registration, production, and commercialization cooperation in China. CFMOTO's U.S. subsidiary has cumulatively received refunds of U.S. tariffs and interest totaling 38.6079 million U.S. dollars, which is expected to affect the company's 2026 net profit by approximately 183 million yuan. Weihua New Materials plans to repurchase shares for 80 million to 120 million yuan, to be used for employee stock ownership plans or equity incentives. Haining Leather City New Energy plans to purchase equity in a total of 38 target photovoltaic companies for 226 million yuan.

CFMOTO announced that its wholly-owned subsidiary CFP has cumulatively received a refund of US tariffs and interest totaling USD 38.6079 million, equivalent to RMB 262 million at the exchange rate. After accounting for the US subsidiary's income tax expenses, it is expected to impact the 2026 net profit by approximately RMB 183 million, representing 10.95% of the most recent audited net profit.